Kornimate/medical-research-clean huggingface dataset:
mobile phone thermal imaging assessment of incompetent perforator veins

Conditions: Chronic Venous Disease

Summary: chronic venous disease is a common disease of the lower limbs. severe cvd can lead to lower limb swelling, pigmentation, and repeated skin ulceration, which seriously affects patients' quality of life. about 10.5% to 92.7% of cvd patients with recurrent varicose veins had insufficient perforating veins. treatment of these ipvs can promote venous ulcer healing and reduce the recurrence rate of venous ulcers. accurate assessment and positioning of insufficient perforating veins in the lower leg is a key step in developing a personalized treatment strategy. at present, color doppler ultrasonography performed in the upright position in combination with the valsalva maneuver or local pressure of the limb is regarded as the "gold standard" for the diagnosis of perforating veins insufficiency. however, in china, a large number of perforating veins insufficiency are diagnosed by venography. because the majority of chinese vascular surgeons are not versatile in vascular ultrasound examination and venous ultrasound protocols vary from institution to institution. a non-functioning valve in an insufficient perforated vein allows blood to flow retrograde from a deep vein to a superficial vein. some researchers have shown that the venous blood temperature of deep veins is higher than that of superficial veins. thus, the retrograde flow of "warm blood" from the deep vein to the superficial vein increases the skin temperature located on the insufficient perforated vein. this study tested the feasibility of a smartphone and its compatible portable thermal imaging device as a tool for assessing insufficient perforated vein. the objective is to study the sensitivity and specificity of smartphone thermal imaging in diagnosing and locating the insufficient perforated vein in cvd patients.


Eligibility criteria:
inclusion criteria: a diagnosis of cvd by vascular surgeon, classified c0 to c6 according to ceap (clinical-etiology - anatomy - pathophysiology) no history of lower extremity surgery the body mass index (bmi) is 18 to 35 kg/m2 exclusion criteria: deep vein thrombosis heart disease peripheral artery disease chronic liver disease chronic kidney disease pregnancy severe obesity (bmi ≥35 kg/m2)
spearhead-3 pediatric study

Conditions: Synovial Sarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neuroblastoma; Osteosarcoma

Summary: this is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in hla-a\*02 eligible and mage-a4 positive subjects aged 2-21 years of age with advanced cancers


Eligibility criteria:
inclusion criteria: * age 2-21 years * body weight ≥ 10 kg * subject has histologically confirmed diagnosis of any one of the following cancers: (a) synovial sarcoma, (b) mpnst, (c) neuroblastoma, or (d) osteosarcoma * must have previously received a systemic chemotherapy * measurable disease according to recist v1.1 (or incr, 2017 neuroblastoma only). * hla-a\*02 positive * tumor shows mage-a4 expression confirmed by central laboratory. * performance status: ecog 0-1 or lansky score ≥ 80 exclusion criteria: * hla-a\*02:05 in either allele; or any a\*02 having same protein sequence as hla-a\*02:05 * history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide. * history of autoimmune or immune mediated disease * known central nervous system (cns) metastases. * other prior malignancy that is not considered by the investigator to be in complete remission * clinically significant cardiovascular disease * active infection with human immunodeficiency virus, hepatitis b virus, hepatitis c virus, or human t cell leukemia virus * pregnant or breastfeeding
results of the application of the clinical pathway of intensified recovery surgery for adults in the processes of total knee and hip replacement at the maz hospital

Conditions: Arthropathy of Knee; Arthropathy of Hip

Summary: the investigators are going to study all the patients who have undergone surgery at the maz hospital from 2019 to the present for knee replacement and hip replacement. the investigators want to analyze the results to see if applying the rica clinical pathway results are better.


Eligibility criteria:
inclusion criteria: * adults, over 18 years old. * diagnosis of moderate-severe gonarthrosis or moderate-severe coxarthrosis. * patients who are operated by orthopedic surgeons at maz hospital with knee or hip arthroplasty. * between january 2019 and june 2022. * asa i-ii-iii. exclusion criteria: * asa iv. * minors.

Keywords: arthroplasty fast-track surgery
urgent medical and surgical conditions during flights

Conditions: Syncope; Arrest; Vertigo; Pain; Chronic Obstructive Pulmonary Disease; Hypertension; CAD

Summary: the aim of this study is to evaluate the incidence and status of urgent medical conditions. after defining the urgent situations, the investigators will evaluate the adequacy of the standard medical kits and trainings.

in this study, the incidence and status of urgent medical conditions, the attitudes of health professionals who encounter such conditions, adequacy of aerospace medical association (asma) suggested medical kits and training of cabin crew in data-received-company aircrafts and the demographic data of patients have been evaluated.

Eligibility criteria:
inclusion criteria: * all passengers (no age limitations) needed urgent medical support during flights exclusion criteria: * patients whom medical urgency records are insufficient

Keywords: inflight emergencies
discontinuation of lens wear in new ortho-k children (doee2)

Conditions: Myopia

Summary: this study aims at investigating the efficacy of myopic control using ortho-k in younger and older children.

children wearing ortho-k have been shown to have slower rate of myopic progression than those wearing single-vision spectacles (cho et al. 2005) or soft lenses (walline et al. 2009). younger myopic children (aged 6-10 years old) may have the faster increase in myopia than old myopic children (aged 11-15 years old), i.e. the rate of myopic progression may be different in different age groups and in children with different refractive status (edwards 1999; fan et al. 2004; cheng et al. 2007). although the refractive correction with ortho-k has been well documented, it is unknown whether the efficiency and reversibility of ortho-k for myopic reduction as well as myopic control are similar in children of different age and refractive groups. in this 14-month study, the eyeball length in 45 younger (6-10 years old) and 45 older (11-15 years old) myopic children before and after ortho-k will be evaluated. eyeball elongation will be determined for the first 7 months when single-vision glasses will be prescribed (phase i) and the next 7 months when ortho-k will be prescribed (phase i). rate of myopic progression will be determined and compared between the two groups of children in the two phases.

Eligibility criteria:
inclusion criteria: * age: between 6 to 15 years old * myopia: between 1.50d and 4.50d in at least one eye * spherical equivalent (se): between -1.00d to -4.50d in both eyes * astigmatism: ≤ 3.00d of axes 180 +/- 30 or ≤ 1.00d of other axes; and the amount is less than refractive sphere * anisometropia: ≤ 1.50d in both refractive sphere, refractive cylinder and se * best corrected monocular visual acuity: equal to or better than 0.10 in logmar scale in both eyes * willingness to wear contact lenses or spectacles on a daily basis * can obtain good ortho-k results with the study lenses * availability for follow-up for at least 14 months exclusion criteria: * strabismus at distance or near * contraindication for contact lens wear and ortho-k (e.g. limbus to limbus corneal cylinder and dislocated corneal apex * systemic or ocular conditions which may affect contact lens wear (e.g. allergy and medication) * systemic or ocular conditions which may affect refractive development (e.g. down syndrome, ptosis) * prior experience with the use of rigid lenses (including ortho-k) * prior experience with myopia control treatment (e.g. refractive therapy or progressive spectacles) * non-compliance to the follow up schedule * non-compliance to the use of the prescribed optical correction * poor ocular response to ortho-k lens wear * significant residual refractive error after ortho-k treatment resulting in poor unaided vision (worse than 0.18 in logmar scale)

Keywords: children corneal reshaping myopia myopia progression orthokeratology
food addiction and hormone study

Conditions: Disordered Eating

Summary: the purpose of this exploratory study is to use electrogastrography (egg) to measure and compare the gastric myoelectrical activity between persons with food addiction (fa) and a control group. additionally, this study will explore if differences exist between perceived hunger and satiety and hormone levels related to hunger and satiety in both groups. the comparison of the egg readings and hormone levels is the next step in furthering our understanding of food addiction and how the physiology - not simply the symptomatology - of fa does or does not relate to weight management.

the study will be conducted over 2 days and will consist of psychological assessments as well as egg measurement (similar to egg) and blood draws to examine hunger and satiety hormones.

Eligibility criteria:
inclusion criteria: * participants will include men and women who identify with weight struggles related to disordered eating and a control sample of people who do not identify with weight issues or disordered eating. must be able to read and write english exclusion criteria: * anyone with a chronic disease including type ii diabetes, hypothyroidism, hypoparathyroidism, cardiovascular disease, cancer of any type * anyone who is currently pregnant, or lactating * medications that may influence or inhibit appetite, sensory functioning, or hormone signaling- e.g. antibiotics, anti-depressants, obesity medications * report of medical condition or surgical intervention that affects swallowing ability * allergy, aversion, or dislike to any of the meal replacements or snacks offered * previous or current diagnosis of a psychiatric illness such as schizophrenia or any other psychotic disorder listed in the dsm-iv or dsm-5 * report of medical conditions that prohibits overnight fasting
a study of lcl161 in combination with weekly paclitaxel in adult patients with advanced solid tumors

Conditions: Solid Tumors

Summary: this is a dose escalation study that will assess the safety and efficacy of lcl161 in combination with weekly paclitaxel in adult patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: patients with breast cancer must have a histologically or cytologically confirmed diagnosis of disease that has metastasized or is resistant to therapy. patients with ovarian cancer must have histological evidence of recurrent epithelial ovarian, fallopian tube or peritoneal cancer. patients must have recovered or stabilized from all toxicities related to their previous treatment except for alopecia male or female patients 18 years or older ecog performance status 0-1 life expectancy greater than 12 weeks measurable disease as determined by recist v1.0 patients must give written informed consent and comply with the protocol exclusion criteria: for patients with breast cancer: concurrent her2-directed or anti-estrogen therapy for patients with ovarian cancer: primary refractory disease, defined as progression during initial treatment with a platinum- and taxane-containing regimen. prior treatment with weekly paclitaxel. more than two chemotherapy regimens given in the relapse setting. evidence of a documented bowel obstruction within six months of study entry patients with unresolved peripheral neuropathy, nausea, vomiting, or diarrhea ≥ ctcae grade 2 any concurrent severe and/or uncontrolled medical conditions that could increase the patient's risk for toxicity while in the study or that could confound discrimination between disease- and study treatment-related toxicities. patients with impairment of gi function or gi disease that may significantly alter the absorption of lcl161 patients who have undergone major surgery ≤ 3 weeks prior to starting study drug or who have not recovered from side effects of procedure. pregnant or breast feeding (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive β-hcg laboratory test (\> 5 miu/ml). known diagnosis of human immunodeficiency virus (hiv) infection or chronic active hepatitis b or c (hiv and hepatitis testing are not mandatory). other protocol-defined inclusion/exclusion criteria may apply

Keywords: lcl161 solid tumors paclitaxel
prone positioning in non-intubated patients with covid-19 associated acute respiratory failure

Conditions: Covid19

Summary: besides protective ventilation with low tidal volumes, prone positioning is a proven intervention to decrease mortality in mechanically ventilated patients with moderate-severe acute respiratory distress syndrome. however, the evidence of this strategy in awake non-intubated patients is scarce. the investigators will perform a randomized controlled trial to define if prone positioning can reduce the requirement of mechanical ventilation.

despite ongoing trials of antivirals and immunomodulatory therapies against covid-19, the treatment of moderate/severe disease is mainly supportive, including oxygen therapy and invasive mechanical ventilation when impending respiratory failure is established. moreover, the associated mortality among mechanically intubated patients is overwhelmingly high. prone position relieves the dependent lung regions from the compressive forces of the mediastinum's weight, leading to homogenization of the gas:tissue ratio between ventral and dorsal lung regions. according to a few case series, and observational non-randomized studies with small sample sizes, there is a consistent improvement in oxygenation in covid-19 patients during prone positioning, however there are no clinical evidence that this improvement is associated with a decrease in the risk of invasive mechanical ventilation. considering that prone positioning is a low cost, low risk and widely available therapy, more high quality evidence is needed, to determine if the benefits of prone positioning in awake patients also include a lower requirement of mechanical ventilation.

Eligibility criteria:
inclusion criteria: * adult patients with confirmed covid-19, and requirement of a fraction of inspired oxygen (fio2) ≥30% through high-flow nasal cannula (hfnc) to maintain a capillary saturation of ≥90% exclusion criteria: * less than 18 years-old * pregnancy * patients with immediate need of invasive mechanical ventilation * contraindications for prone positioning therapy * do-not-resuscitate or do-not-intubate order * refusal of the patient or decision maker to enroll in the study

Keywords: covid-19 severe prone positioning high-flow nasal cannula
post prandial glucose (ppg) study of empagliflozin in japanese patients with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2

Summary: to evaluate the efficacy of empagliflozin administered orally once daily in postprandial glucose and 24-hour glycaemic variability compared to placebo given for 4 weeks as mono-therapy in japanese patients with type 2 diabetes mellitus with insufficient glycaemic control on no antidiabetic treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus prior to informed consent * male and female patients on diet and exercise regimen for 12 weeks prior to informed consent who are: * drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or, * pre-treated with one oral antidiabetic drug (except sulfonylurea and thiazolidinedione); the present antidiabetic therapy has to be unchanged for at least 12 weeks prior to the informed consent. (sulfonylurea is permitted as pre-treatment drug only if the dose is equal or less than a half of daily maximum approval dose.) * glycosylated haemoglobin (hba1c) at visit 1 (screening) * for patients without antidiabetic therapy : hba1c \>=7.0 to =\<10.0% * for patients with one oral antidiabetic drug : hba1c \>=7.0 to =\<9.5% exclusion criteria: * uncontrolled hyperglycaemia with a glucose level \>240 mg/dl (\>13.3 mmol/l) * impaired renal function, defined as estimated glomerular filtration rate (egfr) \<60 ml/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal disease (mdrd) formula) * acute coronary syndrome, stroke or transient ischemic attack (tia) within 12 weeks prior to informed consent * indication of liver disease, defined by serum levels of either alanine transaminase (alt), aspartate transaminase (ast), or alkaline phosphatase (alp) above 3 x upper limit of normal (uln)
brain clock and insulin resistance

Conditions: Insulin Resistance; Type 2 Diabetes

Summary: in this observational cohort study the investigators will determine the activity rhythm of the suprachiasmatic nucleus in humans with progressive stages of insulin resistance, using advanced functional brain imaging (7 tesla functional mri).

type 2 diabetes mellitus (t2dm) has an increasing worldwide incidence. insulin resistance is a key pathophysiological process in the development of hyperglycemia in patients with t2dm. disruption of circadian synchrony leads to insulin resistance. animal studies and post-mortem human brain studies suggest that the master brain clock in the hypothalamic suprachiasmatic nucleus (scn) plays a role in the development of insulin resistance. up to now, no-one has investigated whether the in vivo activity rhythm of the scn is affected in patients with insulin resistance. the investigators hypothesize that the master brain clock has an important role in the development of human insulin resistance.

Eligibility criteria:
inclusion criteria: group 1: obese people with normal insulin sensitivity * age 25-65 years * bmi\>30 * fasting plasma insulin ≤62 pmol/l * fasting plasma glucose \<5.6 mmol/l * homeostatic model assessment for insulin resistance (homa-ir) ≤ 4.5 group 2: obese people with insulin resistance * age 25-65 years * bmi\>30 * fasting plasma insulin \>62 pmol/l * not fulfilling the american diabetes association (ada) criteria for type 2 dm group 3: obese subjects with overt type 2 dm * age 25-65 years * bmi\>30 * diagnosis type 2 dm according to ada criteria exclusion criteria: * an extreme chronotype (midpoint of sleep on free days (msfsc) before 2:00 or after 6:00). * active psychiatric disorder (including circadian rhythm sleep disorder) as defined in diagnostic and statistical manual of mental disorders (dsm) 5 * disorders of the central nervous system (early-onset dementia, stroke, epilepsy, parkinson's disease, brain tumor) * severe visual impairment (who classification) * shift workers * crossing \> 2 time zones in the 3 months before the study * patients with type 2 dm receiving insulin treatment or glucagon-like peptide (glp) 1 agonists * mri contraindications

Keywords: type 2 diabetes mellitus insulin resistance suprachiasmatic nucleus functional mri
gait initiation difficulty and anticipatory postural adjustment (apa) impairment in people with pd - evaluation and training

Conditions: Parkinson Disease(PD)

Summary: gait initiation (gi) difficulty is common in people with parkinson's disease (pd). studies showed that the gi difficulty was related to impaired anticipatory postural adjustments (apa). in healthy people, two phases of apa related center of pressure (cop) shifting were observed before gi. in people with pd, delay and decrease amplitude of apa or abnormal multiple apas were observed during gi. conventional balance tests record the maximum displacement and/or velocity of center of pressure (cop). however, these variables could not show the performance of apa. previous studies suggested that balance and gait initiation were controlled by separate neural circuitries. this could explain why the conventional cop measurement did not correlate to gi very well. it is important to develop gi related apa tests and trainings. researchers found that a perturbation applied before the cop displacement during gi could delay both gi and apa. this indicates that cop displacement has apa components. our pilot study shows that there is a reverse direction of cop displacement before voluntary cop displacement, suggesting the existence of apa. this three year project will evaluate the relationship of the apa of voluntary cop displacement and the apa of gi, establish the apa test for pd, and investigate the effect of apa training on gi in people with pd. in the first year, 20 people without disability will be recruited. the apa before voluntary cop displacement test, apa before gi, and gait performance will be evaluated. in the second year, 15 people with pd and 15 healthy people will be recruited. subjects will receive gi test, gait test, and apa before voluntary cop displacement test. the relationship between different types of apa will be established for pd and healthy people. in the third year, 30 people with pd will be randomized into apa training group, balance group, and control group. the different training effect will be evaluated especially on gi, gait performance, and freezing of gait. this project will advance the knowledge of mechanism of gi difficulty. the result of this project can be applied to clinical rehabilitation of people with gi difficulty.


Eligibility criteria:
health subjects: exclusion criteria: * musculoskeletal injuries on legs. * osteoporosis. pd subjects: inclusion criteria: - clinical diagnosis of parkinson disease. exclusion criteria: * musculoskeletal injuries on legs * osteoporosis. * any peripheral or central nervous system injury or disease patients.

Keywords: gait initiation freezing of gait balance training anticipatory postural adjustments
staccato loxapine in agitated patients with bipolar disorder

Conditions: Bipolar I Disorder

Summary: phase 3 safety and efficacy study of staccato loxapine in the treatment of acute agitation in bipolar 1 disorder patients.

this is an in-clinic, multi-center, randomized, double-blind, placebo-controlled study of 2 dose levels of staccato loxapine, 5 and 10 mg. patients may receive up to 3 doses of study drug in a 24-hour period, depending on their clinical status. the primary endpoint is the change from baseline in the panss (positive and negative symptom scale) excited component (also known as pec) score, performed at 2 hours after the first dose.

Eligibility criteria:
inclusion criteria: * male and female adult patients with bipolar 1 disorder and acute agitation exclusion criteria: * agitation caused primarily by acute intoxication * history of drug or alcohol dependence * treatment with benzodiazepines or other hypnotics within 4 hours prior to study drug administration

Keywords: bipolar 1 disorder, agitation, acute, treatment